Cardiometabolic & kidneyCohort study
Chronic kidney disease and transvenous cardiac implantable electronic device infection—is there an impact on healthcare utilization, costs, disease progression, and mortality?
- Retrospective cohort study
Generalized linear models controlling for other comorbidities
Authors' conclusion
Cardiac implantable electronic device infection in patients with CKD was associated with more healthcare utilization, higher cost, greater disease progression, and greater mortality compared to patients without CKD.
Study context
- Population
- Medicare Fee-for-Service patients implanted with a cardiac implantable electronic device (CIED), July 2016–December 20201.4% with device infection
- Participants
- 584,543 patients
- Exposure
- Chronic kidney disease (CKD) vs no CKD among patients with CIED infection
- Outcome
- Hospital days and costs, post-infection CKD progression and mortality
- Follow-up
- 12 months post-implant
Main finding
As reported in the abstract
CKD
23.5 days
Average total hospital days (infected) · Average cost of infection $121 756
Without CKD
14.5 days
Average total hospital days (infected) · Average cost of infection $55 366
- cost of infection
- incremental cost 66 390 $; P < 0.001
- CKD progression after infection
- HR 1.26; P < 0.001
- mortality after infection
- HR 1.89; P < 0.001
Observational data: associations, not effects.
Further findings
Septicaemia or severe sepsis (infected patients)
P < 0.001
Original publication
Chronic kidney disease and transvenous cardiac implantable electronic device infection—is there an impact on healthcare utilization, costs, disease progression, and mortality? Europace. Published 19 June 2024. doi:10.1093/europace/euae169
Summarised from the published abstract; every number is checked against it